Aemetis Q2 Preview: Can 45Z and Dairy RNG Momentum Survive Q1's 50% EPS Miss?

Q1 improved the numbers, but it did not settle credibility

Aemetis reports on Aug. 6, and the setup remains tight. After a 50% Q1 EPS miss - EPS of -$0.33 versus a -$0.22 estimate - even a cautious outlook could weigh on a stock that appears to trade more on credibility than on headline valuation.

Q1 gave investors enough improvement to matter, but not enough to erase skepticism. Aemetis delivered 27% revenue growth, reported gross profit of $2.8 million, and operating loss improved approximately 60%. That looks like real operational progress.

The debate into this quarter is straightforward. Bulls can point to growing revenue, positive gross profit, and a much narrower operating loss. Bears can argue that one quarter may still reflect favorable credit mix or temporary cost relief, so the real test is whether those gains repeat. If management shows consistency, the stock has a case for a turnaround re-rating. If not, investors may treat the prior miss as part of a broader pattern.

Four operating threads will shape the Q2 read

One quarter does not settle the story. The more important question is whether management can show four operating areas moving together. If they do, investors are more likely to start underwriting repeatability. If not, it will be easy to focus on one bright spot and dismiss the rest.

Keyes ethanol is now an efficiency test

The latest Keyes update is logistical rather than financial, but it still matters: Keyes mechanical vapor recompression equipment delivery has begun. MVR is primarily an efficiency project, so the real question is whether it can eventually lower energy intensity and support uptime.

That makes the equipment headline useful, but not conclusive. Until the system runs at scale, delivery is a milestone, not proof of future margins.

Dairy RNG is the clearest volume-driven improvement

This remains the most tangible Q1 improvement. biogas RNG sales volume grew 55% to 110,000 MMBtu, and Revenues of $54.6 million, an increase of 27% came alongside that production gain. That is evidence of volume translating into revenue.

The credit mix is the other thing to watch. Aemetis said revenues included LCFS credits earned from seven Dairy RNG pathways with an average CI score of negative 380, versus the negative 150 default pathway that applied for Q1 2025 revenues, with 6 additional biogas pathways nearing approval. Better pathways can help margin quality, but investors should still distinguish between what the current mix did in Q1 and what additional approvals could do in later quarters.

Section 45Z needs to prove it can repeat

Q1 also introduced a new policy variable: $4.0 million of Section 45Z Production Tax Credits recognized in Q1 2026. That is encouraging, but its value depends on whether it becomes a repeatable quarterly outcome tied to production.

For Q2, the question is not whether 45Z exists. It is whether management can frame it as a consistent production-related benefit rather than a one-quarter accounting headline.

India still looks more like upside optionality than a core driver

India Biodiesel revenue of $10.5 million in revenue with the resumption of OMC tender shipments under new contracts is not large enough to carry the whole model. Still, it is useful as a read on demand recovery and execution. If tender shipments are genuinely resuming under new contracts, India looks less like a cleanup story and more like a secondary upside leg.

What to watch on the call: - Ethanol: Does management connect equipment delivery to a realistic commissioning and efficiency story? - Dairy RNG: Do volumes, revenue, and pathway progress explain the Q1 improvement, or is credit mix doing most of the work? - 45Z: Is the credit described as a repeating production outcome? - India: Does revenue look contract-supported rather than incidental?

If three of these four areas hold up, the quarter becomes harder to dismiss as one-off luck.

The next credibility test is financing and scale

The next step in Aemetis' story is not simply more good news. It is showing that earlier good news can move from project milestones to repeatable financial execution.

Financing is the clearest new variable

The most important new development is financial, not operational. Earlier this month, the CPCFA adopted an initial resolution supporting up to $1.1 billion of tax-exempt financing. That is a meaningful signal, but it is still a support step rather than completed funding.

On the call, the useful update is not another broad statement about potential. It is progress on structure, timing, and how the capital would support projects, working capital, and execution.

Equipment delivery has to become an execution story

Likewise, Aemetis Receives Key Equipment for Mechanical Vapor Recompression at Ethanol Plant matters, but only if it starts to lead into commissioning and measurable performance gains. Delivery is the first step, not the final proof.

What would actually strengthen the thesis

The case for Aemetis becomes stronger when management can show: - financing is moving from resolution language toward binding terms - equipment receipt is tied to a commissioning timeline and expected efficiency benefit - prior operational gains can scale without constantly running into a fresh capital constraint

If that happens, investors have a clearer basis for treating Q1 as the start of a turnaround rather than an isolated cleaner quarter. If not, the stock is likely to remain judged more on promise than on proof.